Target intelligence / Profile preview

Perforin-1 (PRF1)

Target
PRF1
Molecular classification
Pore-forming protein, Immune effector protein, MACPF domain protein (membrane attack complex/perforin), Other
01

Overview

Perforin-1 (PRF1) is a calcium-dependent pore-forming immune protein encoded by the PRF1 gene and found predominantly in cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Upon immune cell activation, perforin is released from cytolytic granules and inserts into the target cell membrane, oligomerizing to form transmembrane pores. These pores allow the rapid entry of pro-apoptotic granzymes, leading to programmed cell death (apoptosis) of infected, malignant, or otherwise abnormal cells. The protein is structurally homologous to complement component C9 and contains a MACPF domain critical for pore formation. Mutations in PRF1 underlie familial hemophagocytic lymphohistiocytosis type 2 and contribute to impaired immune surveillance, with increased risk of immune dysregulation and cancer.

Other names
PerforinPFPP1HPLH2CytolysinLymphocyte pore-forming proteinperforin 1 (pore forming protein)perforin-1cytolysinlymphocyte pore-forming proteinperforin 1 (preforming protein)
02

Mechanism of action

Not applicable for approved drugs; experimental agents or research inhibitors may act by blocking PRF1 expression, polymerization, or pore-forming function.

03

Biological functions

Immune responseCytolysis of target cellsApoptosis inductionRegulation of immune homeostasisDestruction of virus-infected and transformed (cancer) cellsElimination of unneeded T cells
04

Disease associations

Hemophagocytic lymphohistiocytosis (FHL, especially FHL2)Cancer (leukemia, lymphoma)Autoimmune lymphoproliferative syndrome (ALPS)Aplastic anemiaDiabetesMultiple sclerosisOther immunodeficiencies and immune dysregulation syndromes
05

Safety considerations

Deficiency or mutation in PRF1 can lead to life-threatening immune dysregulation (FHL)Loss of function increases cancer riskOveractivation could cause excessive tissue damage/inflammation
06

Interacting drugs

No direct, clinically-approved drugs are currently known to target or modulate perforin-1 in humans. Modulation is mainly of experimental or theoretical interest.
07

Biomarkers

PRF1 expression/mutation status in familial hemophagocytic lymphohistiocytosis or some cancersPerforin protein levels may be monitored in research or diagnostic settings for immune competence or disorders.

Beyond the preview

Go deeper on Perforin-1 (PRF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perforin-1 (PRF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call